Impact News +++ Kapitalerhöhung mit hohem Abschlag: Aktie von Coherus BioSciences bricht ein/n (Investing.com DE) +++ COHERUS Aktie +5,51%

OPUS GENETICS Aktie

>OPUS GENETICS Aktienkurs

2.77 EUR -3.3% (TradegateBSX)

Ask: 2.925 EUR / 1100 Stück

Bid: 2.85 EUR / 1100 Stück

Tagesumsatz: 1397 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>OPUS GENETICS Performance

1 Woche: +28,5%

1 Monat: +72,6%

3 Monate: +70,7%

6 Monate: +209,5%

1 Jahr: +156,1%

laufendes Jahr: +67,7%

>OPUS GENETICS Aktie

Name:

OPUS GENETICS DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US67577R1023 / A2QG4Z

Symbol/ Ticker:

R3X1 (Frankfurt)

Kürzel:

FRA:R3X1, ETR:R3X1, R3X1:GR

Index:

Webseite:

https://opusgtx.com/

Profil:

Opus Genetics Inc. is a biotechnology company focu..
>Volltext..

Marktkapitalisierung:

195.89 Mio. EUR

Unternehmenswert:

170.51 Mio. EUR

Umsatz:

12.3 Mio. EUR

EBITDA:

-31.2 Mio. EUR

Nettogewinn:

-57.32 Mio. EUR

Gewinn je Aktie:

-1.44 EUR

Schulden:

0.9 Mio. EUR

Liquide Mittel:

25.9 Mio. EUR

Operativer Cashflow:

-27.61 Mio. EUR

Bargeldquote:

1.06

Umsatzwachstum:

65.67%

Gewinnwachstum:

-137.99%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

OPUS GENETICS

Letzte Datenerhebung:

13.02.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 68.96 Mio. St.

Frei handelbar: 75.27%

Leerverk. Aktien: -

Rückkaufquote: -10.65%

Mitarbeiter: 18

Umsatz/Mitarb.: 0.51 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 173.65%

Bewertung:

KGV: -

KGV lG: -

KUV: 13.63

KBV: 30.78

PEG-Ratio: -0.03

EV/EBITDA: -

Rentabilität:

Bruttomarge: 99.66%

Gewinnmarge: -466.09%

Operative Marge: -254.05%

Managementeffizenz:

Gesamtkaprendite: -178.28%

Eigenkaprendite: -338.75%

>Peer Group

Gesundheit, Augenmedizin, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>OPUS GENETICS Chart & Kurs - Tradegate

>OPUS GENETICS News

13.02.26 - 14:06	Opus Genetics higher after $25M private placement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.02.26 - 13:33	Opus Genetics Announces $25 Million Private Placement (GlobeNewswire EN)
	Opus Genetics Announces $25 Million Private Placement...

02.02.26 - 14:03	Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 (GlobeNewswire EN)
	Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026...

28.01.26 - 13:21	Where Opus Genetics Stands With Analysts (Benzinga)
	Importance Rank: 1 read more...

27.01.26 - 13:06	Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa (GlobeNewswire EN)
	Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa...

16.12.25 - 22:03	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...

11.12.25 - 13:03	Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire EN)
	Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference...

09.12.25 - 19:06	Opus Genetics rises as eye disease study to proceed without changes (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.12.25 - 13:03	Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease (GlobeNewswire EN)
	Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial...

02.12.25 - 22:03	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...

12.11.25 - 16:00	Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
	Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +14.29% and +11.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.11.25 - 13:42	Opus Genetics GAAP EPS of -$0.25 misses by $0.12, revenue of $3.08M in-line (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.11.25 - 17:30	Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
	Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

14.10.25 - 14:03	Opus Genetics to Participate in Chardan′s 9th Annual Genetic Medicines Conference (GlobeNewswire EN)
	Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference...

01.10.25 - 19:45	Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice (Zacks)
	Does Opus Genetics, Inc. (IRD) have what it takes to be a top stock pick for momentum investors? Let's find out....

30.09.25 - 13:03	Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) (GlobeNewswire EN)
	Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)...

16.09.25 - 11:30	Zacks.com featured highlights include Sally Beauty, Broadstone Net Lease and Opus Genetics (Zacks)
	Sally Beauty, Broadstone Net Lease, and Opus Genetics make Zacks' "Under $20 Breakout Trio" list for investors eyeing growth....

15.09.25 - 22:45	The Under $20 Breakout Trio Investors Shouldn′t Ignore (Zacks)
	Sally Beauty, Broadstone Net Lease and Opus Genetics emerge as today's breakout stock picks under $20, flagged for potential near-term gains....

12.09.25 - 14:03	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...

04.09.25 - 14:03	Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire EN)
	Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Visual Disturbances...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Weiber lächeln, wenn sie grüßen. - Jean Paul

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram